Skip to main content
Premium Trial:

Request an Annual Quote

NantHealth, Providence Health to Establish Clinical WGS Program for Cancer Patients

NEW YORK (GenomeWeb) – NantHealth, The Chan Soon-Shiong Institute of Molecular Medicine, and Providence Health and Services will partner to create a clinical network for whole-genome sequencing.

The organizations have installed an Illumina HiSeq X Ten sequencing system and plan to establish a CLIA-approved facility to use sequencing to help guide treatment decisions for cancer patients. The clinical lab will be located at NantOmics in Culver City, Calif., and will have the capacity for 22 HiSeq X Ten systems.

Providence Health and Services will perform whole-genome sequencing as well as transcriptome sequencing and proteomics on all newly diagnosed cancer patients, approximately 20,000 per year.

In addition, the partners will use NantHealth's supercomputer, which, according to the firm, can analyze genomic data from a tumor sample in 47 seconds.

"Our super-computer-driven analysis represents more than just cutting edge 21st-century clinical decision support representing the next chapter in the medical community's fight against disease," Patrick Soon-Shiong, the founder and chairman of NantHealth, said in a statement. "We are now able to better understand the depth and extent of analysis required to deliver more targeted, effective and efficient treatment for patients."

"Through this partnership, we are radically improving accuracy," Rod Hochman, president and CEO of Providence Health and Services, said in a statement. "Doctors will have the information to meaningfully transform the lives of our patients by giving them a real chance of beating cancer."

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.